Partial rescue of neonatal lethality of Dhcr7 null mice by a nestin promoter-driven DHCR7 transgene expression.
In humans, genetic disorders affecting post-squalene cholesterol biosynthesis result in a variety of dysmorphology syndromes. One key feature of all of these is the presence of mental retardation and another is the lack of a robust genotype-phenotype correlation. Knockout mice defective in the 3beta hydroxysterol Delta7 reductase (Dhcr7), a model for the most common of such disorders in humans, the Smith-Lemli-Opitz syndrome, all die within 24 h of birth. The cause of this postnatal mortality in these mice has not been fully established. In the present study, we tested the hypothesis that CNS dysfunction was a major cause of this lethality and investigated whether transgenic expression of normal human DHCR7 in neuronal tissues could rescue this neonatal lethality. Transgenic mice, expressing DHCR7 driven by murine nestin promoter, were bred onto Dhcr7 knock-out (Dhcr7(-1-)) background and resulted in a partial rescue of neonatal lethality in 11 of 91 (12%) of transgene-positive Dhcr7(-1-) pups. Despite biochemical analyses that showed continued profound cholesterol deficiency in brain, rescued animals survived between 3 and 17 days. Thus, one important conclusion to be drawn is that defects in CNS in Dhcr7 knockout mice may contribute to the early lethality. Another conclusion is that even small and subtle changes in the brain sterol metabolism were sufficient to enable rescue. These data also provide important clues as to the cause of the variable expressivity seen in SLOS.
Yu
Hongwei
H
Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, STR 541, 114 Doughty Street, Charleston, SC 29403, USA. yuh@musc.edu
Wessels
Andy
A
Tint
G Stephen
GS
Patel
Shailendra B
SB
D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D015152:Blotting, Northern / Q000379:methods; D001921:Brain / Q000254:growth & development / Q000378:metabolism; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D018390:Gene Targeting / Q000379:methods; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007381:Intermediate Filament Proteins / Q000235:genetics*; D007668:Kidney / Q000254:growth & development / Q000378:metabolism; D008099:Liver / Q000254:growth & development / Q000378:metabolism; D008168:Lung / Q000254:growth & development / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic / Q000254:growth & development / Q000378:metabolism; D046529:Microscopy, Electron, Transmission / Q000379:methods; D008967:Molecular Biology / Q000379:methods; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics*; D064231:Nestin; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D011401:Promoter Regions, Genetic / Q000502:physiology*; D013116:Spinal Cord / Q000254:growth & development / Q000648:ultrastructure; D013261:Sterols / Q000378:metabolism; D019076:Transgenes / Q000502:physiology*
D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; C577485:Nes protein, mouse; D064231:Nestin; D013261:Sterols; D044925:Oxidoreductases Acting on CH-CH Group Donors; C019995:7-dehydrocholesterol reductase